Tumor doubling time predicts response to sorafenib in radioactive iodine-refractory differentiated thyroid cancer.

In conclusion, small tumor size and long doubling time of each target lesion can be a prognostic marker to predict the responsiveness to sorafenib in RAI-refractory DTC patients. PMID: 31006722 [PubMed - as supplied by publisher]
Source: Endocrine Journal - Category: Endocrinology Tags: Endocr J Source Type: research